Your browser doesn't support javascript.
loading
Structure of lipoprotein lipase in complex with GPIHBP1.
Arora, Rishi; Nimonkar, Amitabh V; Baird, Daniel; Wang, Chunhua; Chiu, Chun-Hao; Horton, Patricia A; Hanrahan, Susan; Cubbon, Rose; Weldon, Stephen; Tschantz, William R; Mueller, Sascha; Brunner, Reto; Lehr, Philipp; Meier, Peter; Ottl, Johannes; Voznesensky, Andrei; Pandey, Pramod; Smith, Thomas M; Stojanovic, Aleksandar; Flyer, Alec; Benson, Timothy E; Romanowski, Michael J; Trauger, John W.
Afiliação
  • Arora R; Chemical Biology and Therapeutics, Novartis Institutes for Biomedical Research, Cambridge, MA 02139.
  • Nimonkar AV; Cardiovascular and Metabolic Disease Area, Novartis Institutes for Biomedical Research, Cambridge, MA 02139.
  • Baird D; Chemical Biology and Therapeutics, Novartis Institutes for Biomedical Research, Cambridge, MA 02139.
  • Wang C; Chemical Biology and Therapeutics, Novartis Institutes for Biomedical Research, Cambridge, MA 02139.
  • Chiu CH; Chemical Biology and Therapeutics, Novartis Institutes for Biomedical Research, Cambridge, MA 02139.
  • Horton PA; Chemical Biology and Therapeutics, Novartis Institutes for Biomedical Research, Cambridge, MA 02139.
  • Hanrahan S; Cardiovascular and Metabolic Disease Area, Novartis Institutes for Biomedical Research, Cambridge, MA 02139.
  • Cubbon R; Cardiovascular and Metabolic Disease Area, Novartis Institutes for Biomedical Research, Cambridge, MA 02139.
  • Weldon S; Biotherapeutic and Analytical Technologies, Novartis Institutes for Biomedical Research, Cambridge, MA 02139.
  • Tschantz WR; Biotherapeutic and Analytical Technologies, Novartis Institutes for Biomedical Research, Cambridge, MA 02139.
  • Mueller S; Global Discovery Chemistry, Novartis Institutes for Biomedical Research, 4002 Basel, Switzerland.
  • Brunner R; Chemical Biology and Therapeutics, 4002 Basel, Switzerland.
  • Lehr P; Global Discovery Chemistry, Novartis Institutes for Biomedical Research, 4002 Basel, Switzerland.
  • Meier P; Global Discovery Chemistry, Novartis Institutes for Biomedical Research, 4002 Basel, Switzerland.
  • Ottl J; Chemical Biology and Therapeutics, 4002 Basel, Switzerland.
  • Voznesensky A; Biotherapeutic and Analytical Technologies, Novartis Institutes for Biomedical Research, Cambridge, MA 02139.
  • Pandey P; Chemical Biology and Therapeutics, Novartis Institutes for Biomedical Research, Cambridge, MA 02139.
  • Smith TM; Chemical Biology and Therapeutics, Novartis Institutes for Biomedical Research, Cambridge, MA 02139.
  • Stojanovic A; Global Discovery Chemistry, Novartis Institutes for Biomedical Research, 4002 Basel, Switzerland.
  • Flyer A; Global Discovery Chemistry, Novartis Institutes for Biomedical Research, Cambridge, MA 02139.
  • Benson TE; Chemical Biology and Therapeutics, Novartis Institutes for Biomedical Research, Cambridge, MA 02139.
  • Romanowski MJ; Chemical Biology and Therapeutics, Novartis Institutes for Biomedical Research, Cambridge, MA 02139; michael.romanowski@novartis.com john.trauger@novartis.com.
  • Trauger JW; Cardiovascular and Metabolic Disease Area, Novartis Institutes for Biomedical Research, Cambridge, MA 02139; michael.romanowski@novartis.com john.trauger@novartis.com.
Proc Natl Acad Sci U S A ; 116(21): 10360-10365, 2019 05 21.
Article em En | MEDLINE | ID: mdl-31072929
ABSTRACT
Lipoprotein lipase (LPL) plays a central role in triglyceride (TG) metabolism. By catalyzing the hydrolysis of TGs present in TG-rich lipoproteins (TRLs), LPL facilitates TG utilization and regulates circulating TG and TRL concentrations. Until very recently, structural information for LPL was limited to homology models, presumably due to the propensity of LPL to unfold and aggregate. By coexpressing LPL with a soluble variant of its accessory protein glycosylphosphatidylinositol-anchored high-density lipoprotein binding protein 1 (GPIHBP1) and with its chaperone protein lipase maturation factor 1 (LMF1), we obtained a stable and homogenous LPL/GPIHBP1 complex that was suitable for structure determination. We report here X-ray crystal structures of human LPL in complex with human GPIHBP1 at 2.5-3.0 Å resolution, including a structure with a novel inhibitor bound to LPL. Binding of the inhibitor resulted in ordering of the LPL lid and lipid-binding regions and thus enabled determination of the first crystal structure of LPL that includes these important regions of the protein. It was assumed for many years that LPL was only active as a homodimer. The structures and additional biochemical data reported here are consistent with a new report that LPL, in complex with GPIHBP1, can be active as a monomeric 11 complex. The crystal structures illuminate the structural basis for LPL-mediated TRL lipolysis as well as LPL stabilization and transport by GPIHBP1.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Receptores de Lipoproteínas / Lipase Lipoproteica Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Receptores de Lipoproteínas / Lipase Lipoproteica Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2019 Tipo de documento: Article